Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies

Mona Noori Koopaei1, Rassoul Dinarvand1,2, Mohsen Amini3, Hojatollah Rabbani4, Shaghayegh Emami4, Seyed Nasser Ostad5, Fatemeh Atyabi1,21Novel Drug Delivery Laboratory, Faculty of Pharmacy, 2Nanotechnology Research Center, 3Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Noori Koopaei M, Dinarv, R, Amini M, Rabbani H, Emami S, Ostad SN, Atyabi F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/de02f899e15d4fc59bf55fc3b443a105
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de02f899e15d4fc59bf55fc3b443a105
record_format	dspace
spelling	oai:doaj.org-article:de02f899e15d4fc59bf55fc3b443a1052021-12-02T02:42:16ZDocetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies1176-91141178-2013https://doaj.org/article/de02f899e15d4fc59bf55fc3b443a1052011-09-01T00:00:00Zhttp://www.dovepress.com/docetaxel-immunonanocarriers-as-targeted-delivery-systems-for-her2-pos-a8243https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Mona Noori Koopaei1, Rassoul Dinarvand1,2, Mohsen Amini3, Hojatollah Rabbani4, Shaghayegh Emami4, Seyed Nasser Ostad5, Fatemeh Atyabi1,21Novel Drug Delivery Laboratory, Faculty of Pharmacy, 2Nanotechnology Research Center, 3Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 4Monoclonal Antibody Research Center, Avesina Research Institute, ACECR, Tehran, Iran; 5Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, IranBackground: The objective of this study was to develop pegylated poly lactide-co-glycolide acid (PLGA) immunonanocarriers for targeting delivery of docetaxel to human breast cancer cells.Methods: The polyethylene glycol (PEG) groups on the surface of the PLGA nanoparticles were functionalized using maleimide groups. Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) antigens of cancer cells, used as the targeting moiety, was attached to the maleimide groups on the surface of pegylated PLGA nanoparticles. Nanoparticles prepared by a nanoprecipitation method were characterized for their size, size distribution, surface charge, surface morphology, drug-loading, and in vitro drug release profile.Results: The average size of the trastuzumab-decorated nanoparticles was 254 &plusmn; 16.4 nm and their zeta potential was -11.5 &plusmn; 1.4 mV. The average size of the nontargeted PLGA nanoparticles was 183 &plusmn; 22 nm and their zeta potential was -2.6 &plusmn; 0.34 mV. The cellular uptake of nanoparticles was studied using both HER2-positive (SKBR3 and BT-474) and HER2-negative (Calu-6) cell lines.Conclusion: The cytotoxicity of the immunonanocarriers against HER2-positive cell lines was significantly higher than that of nontargeted PLGA nanoparticles and free docetaxel.Keywords: nanoparticles, drug targeting, immunonanocarriers, trastuzumab, docetaxel, PLGA, HER2 receptorNoori Koopaei MDinarvRAmini MRabbani HEmami SOstad SNAtyabi FDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2011, Iss default, Pp 1903-1912 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Noori Koopaei M Dinarv R Amini M Rabbani H Emami S Ostad SN Atyabi F Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
description	Mona Noori Koopaei1, Rassoul Dinarvand1,2, Mohsen Amini3, Hojatollah Rabbani4, Shaghayegh Emami4, Seyed Nasser Ostad5, Fatemeh Atyabi1,21Novel Drug Delivery Laboratory, Faculty of Pharmacy, 2Nanotechnology Research Center, 3Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 4Monoclonal Antibody Research Center, Avesina Research Institute, ACECR, Tehran, Iran; 5Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, IranBackground: The objective of this study was to develop pegylated poly lactide-co-glycolide acid (PLGA) immunonanocarriers for targeting delivery of docetaxel to human breast cancer cells.Methods: The polyethylene glycol (PEG) groups on the surface of the PLGA nanoparticles were functionalized using maleimide groups. Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) antigens of cancer cells, used as the targeting moiety, was attached to the maleimide groups on the surface of pegylated PLGA nanoparticles. Nanoparticles prepared by a nanoprecipitation method were characterized for their size, size distribution, surface charge, surface morphology, drug-loading, and in vitro drug release profile.Results: The average size of the trastuzumab-decorated nanoparticles was 254 &plusmn; 16.4 nm and their zeta potential was -11.5 &plusmn; 1.4 mV. The average size of the nontargeted PLGA nanoparticles was 183 &plusmn; 22 nm and their zeta potential was -2.6 &plusmn; 0.34 mV. The cellular uptake of nanoparticles was studied using both HER2-positive (SKBR3 and BT-474) and HER2-negative (Calu-6) cell lines.Conclusion: The cytotoxicity of the immunonanocarriers against HER2-positive cell lines was significantly higher than that of nontargeted PLGA nanoparticles and free docetaxel.Keywords: nanoparticles, drug targeting, immunonanocarriers, trastuzumab, docetaxel, PLGA, HER2 receptor
format	article
author	Noori Koopaei M Dinarv R Amini M Rabbani H Emami S Ostad SN Atyabi F
author_facet	Noori Koopaei M Dinarv R Amini M Rabbani H Emami S Ostad SN Atyabi F
author_sort	Noori Koopaei M
title	Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
title_short	Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
title_full	Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
title_fullStr	Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
title_full_unstemmed	Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
title_sort	docetaxel immunonanocarriers as targeted delivery systems for her2-positive tumor cells: preparation, characterization, and cytotoxicity studies
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/de02f899e15d4fc59bf55fc3b443a105
work_keys_str_mv	AT noorikoopaeim docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies AT dinarv docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies AT r docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies AT aminim docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies AT rabbanih docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies AT emamis docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies AT ostadsn docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies AT atyabif docetaxelimmunonanocarriersastargeteddeliverysystemsforher2positivetumorcellspreparationcharacterizationandcytotoxicitystudies
_version_	1718402254597259264

Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies

Ejemplares similares